文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]F-AraG在椎体骨髓中的摄取可能预测接受抗PD-(L)1免疫治疗的非小细胞肺癌患者的生存

[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
PubMed 文献 · J Nucl Med · 2024-12-03

本研究纳入11例晚期非小细胞肺癌患者,在开始免疫治疗前进行[18F]F-AraG PET显像,评估全身免疫状态。结果显示腰椎和骶椎骨髓[18F]F-AraG SUVtotal可区分治疗进展与未进展患者,准确率分别为90.9%和81.8%;腰椎骨髓高信号患者生存概率显著低于低信号患者(P=0.0003)。

要点

  • 11例晚期NSCLC患者免疫治疗前接受[18F]F-AraG PET显像。
  • 腰椎和骶椎骨髓[18F]F-AraG SUVtotal区分进展与否准确率分别为90.9%和81.8%。
  • 腰椎骨髓高[18F]F-AraG SUVtotal患者生存概率显著低于低信号者(P=0.0003)。

核心结论

  • 本研究强调评估全身免疫的重要性,并提示[18F]F-AraG骨髓信号有潜力作为预测性影像生物标志物用于患者分层和治疗指导。

研究设计与样本

  • 11例晚期非小细胞肺癌患者在开始免疫治疗前接受[18F]F-AraG PET显像,并分析诊断性[18F]FDG PET/CT以评估疾病范围差异。
  • 从基线[18F]F-AraG扫描中提取所有肿瘤病灶、活动性淋巴结、脾、椎体骨髓、肝、甲状腺、心脏和肠道的SUVmax、SUVmean和SUVtotal,进行判别分析和Kaplan-Meier分析以检验其预测患者反应和总生存的能力。

主要发现

  • 患者队列中疾病范围存在差异,但[18F]FDG生物标志物(SUVmax、总代谢肿瘤体积和总病灶糖酵解)均不能预测患者生存。
  • 在病灶内和病灶间均观察到[18F]F-AraG与[18F]FDG分布的差异,证实二者捕捉肿瘤微环境的不同方面。
  • 在所研究的3个SUV参数中,[18F]F-AraG SUVtotal提供了适合按免疫活性对肿瘤或患者进行分层的动态范围。
  • 腰椎和骶椎骨髓[18F]F-AraG SUVtotal区分治疗进展与未进展患者的准确率分别为90.9%和81.8%。
  • Kaplan-Meier分析显示腰椎骨髓高[18F]F-AraG SUVtotal患者生存概率显著低于低信号患者(P=0.0003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the systemic impact of both cancer and the associated immune response, immuno-PET is predominantly centered on assessment of the immune milieu within the tumor microenvironment. The aim of this study was to assess the value of [18F]F-AraG PET imaging as a noninvasive method for evaluation of system-wide immune status of patients with non-small cell lung cancer before starting immunotherapy. Methods: Eleven patients with advanced non-small cell lung cancer were imaged with [18F]F-AraG before starting immunotherapy. Diagnostic [18F]FDG PET/CT scans were analyzed to assess differences in the extent of disease among patients. SUVmax, SUVmean, and total SUV (SUVtotal) from all tumor lesions, active lymph nodes, spleen, vertebral bone marrow, liver, thyroid, heart, and bowel were extracted from the baseline [18F]F-AraG scans, and discriminant and Kaplan-Meier analyses were performed to test their ability to predict patient response and overall survival. Results: The extent of the disease was variable in the patient cohort, but none of the [18F]FDG biomarkers associated with tumor burden (SUVmax, total metabolic tumor volume, and total lesion glycolysis) was predictive of patient survival. The differences in the [18F]F-AraG and [18F]FDG distribution were observed both within and between lesions, confirming that they capture distinct aspects of the tumor microenvironment. Of the 3 SUV parameters studied, [18F]F-AraG SUVtotal provided a dynamic range suitable for stratifying tumors or patients according to their immune activity. [18F]F-AraG SUVtotal measured in the lumbar and sacral vertebrae differentiated between patients who progressed on therapy and those who did not with 90.9% and 81.8% accuracy, respectively. The Kaplan-Meier analysis revealed that patients with high [18F]F-AraG SUVtotal in the lumbar bone marrow had significantly lower probability of survival than those with a low signal (P = 0.0003). Conclusion: This study highlights the significance of assessing systemic immunity and indicates the potential of the [18F]F-AraG bone marrow signal as a predictive imaging biomarker for patient stratification and treatment guidance.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Levi J, Das M, Vasanawala MS, et al. [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. J Nucl Med. 2024. PMID: 39448270. doi:10.2967/jnumed.124.268253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。